Zeneca and UK Imperial Cancer Research Fund (ICRF) collaborate on cancer diagnostics
This article was originally published in Clinica
Executive Summary
Zeneca and the UK Imperial Cancer Research Fund (ICRF) have formed a partnership to develop DNA diagnostics for cancer. A joint committee will pick commercial prospects from targets identified by ICRF. Both organisations will be involved in early development. Clinical evaluation will be conducted by the ICRF and Zeneca will commercialise successful tests. The deal will provide ICRF with £1.2 million ($1.8 million) in research funding plus royalties on sales of diagnostic products.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.